- Conditions
- IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
- Interventions
- Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
- Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 722
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma, Brain Neoplasms
- Interventions
- NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
- Device · Procedure · Genetic
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • St Louis, Missouri
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Plus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 3
- States / cities
- Manhasset, New York • Dallas, Texas • San Antonio, Texas
- Conditions
- Glioblastoma
- Interventions
- Abemaciclib, Surgery
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- CAR.B7-H3T cells infusion
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Recurrent Glioblastoma
- Interventions
- CART-EGFR-IL13Ra2 T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer
- Interventions
- forodesine hydrochloride
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Glioma, Malignant
- Interventions
- D2C7-IT, 2141-V11
- Drug
- Lead sponsor
- Darell Bigner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Interventions
- C5252
- Biological
- Lead sponsor
- ImmVira Pharma Co. Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- cintredekin besudotox, adjuvant therapy, conventional surgery, neoadjuvant therapy
- Biological · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- porfimer sodium, adjuvant therapy, conventional surgery
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 73 more
- Conditions
- Recurrent Medulloblastoma
- Interventions
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years to 39 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- BGB 324 (before surgery), BGB 324 (after surgery)
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Detroit, Michigan + 3 more
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- filgrastim, exatecan mesylate
- Biological · Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 4
- States / cities
- New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
- Conditions
- High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
- Interventions
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Fullerton, California • Newport Beach, California • Santa Monica, California
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- atrasentan hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Glioblastoma
- Interventions
- Ad-RTS-hIL-12, veledimex, Nivolumab
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
- Conditions
- Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
- Interventions
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection
- Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Amgen 386, Bevacizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more
- Conditions
- Recurrent Glioblastoma, Brain Tumor
- Interventions
- Cediranib, Lomustine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma Multiforme, Meningioma
- Interventions
- Ribociclib
- Drug
- Lead sponsor
- Nader Sanai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
- Interventions
- CYNK001-IV, CYNK001-IT
- Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas